Mathieu R. Brodeur

发表

Reduction of Advanced-Glycation End Products Levels and Inhibition of RAGE Signaling Decreases Rat Vascular Calcification Induced by Diabetes

J. Leblond, D. Deblois, P. Moreau, 2014, PloS one.

Expression of caveolin‐1 in hepatic cells increases oxidized LDL uptake and preserves the expression of lipoprotein receptors

L. Falstrault, D. Rhainds, L. Brissette, 2009, Journal of cellular biochemistry.

Influence of oxidized low-density lipoproteins (LDL) on the viability of osteoblastic cells.

L. Falstrault, L. Brissette, R. Moreau, 2008, Free radical biology & medicine.

HDL3 reduces the association and modulates the metabolism of oxidized LDL by osteoblastic cells: A protection against cell death

L. Falstrault, L. Brissette, R. Moreau, 2008, Journal of cellular biochemistry.

Scavenger Receptor of Class B Expressed by Osteoblastic Cells Are Implicated in the Uptake of Cholesteryl Ester and Estradiol From LDL and HDL3

L. Falstrault, L. Brissette, R. Moreau, 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Physiological importance of SR-BI in the in vivo metabolism of human HDL and LDL in male and female mice Published, JLR Papers in Press, January 16, 2005. DOI 10.1194/jlr.M400165-JLR200

L. Falstrault, L. Brissette, G. Bourret, 2005, Journal of Lipid Research.

Investigational drugs in development for hypertriglyceridemia: a coming-of-age story

J. Tardif, D. Rhainds, Mathieu R. Brodeur, 2019, Expert opinion on investigational drugs.

The role of human and mouse hepatic scavenger receptor class B type I (SR-BI) in the selective uptake of low-density lipoprotein-cholesteryl esters.

L. Falstrault, D. Rhainds, L. Brissette, 2003, Biochemistry.

SR‐BI, CD36, and caveolin‐1 contribute positively to cholesterol efflux in hepatic cells

L. Falstrault, L. Brissette, Mathieu R. Brodeur, 2010, Cell biochemistry and function.

Apolipoprotein C-I reduces cholesteryl esters selective uptake from LDL and HDL by binding to HepG2 cells and lipoproteins.

L. Falstrault, L. Brissette, V. Krasteva, 2010, Biochimica et biophysica acta.

The interleukin-1β modulator gevokizumab reduces neointimal proliferation and improves reendothelialization in a rat carotid denudation model.

J. Tardif, F. Roubille, É. Rhéaume, 2014, Atherosclerosis.

Palmitic Acid Increases Medial Calcification by Inducing Oxidative Stress

P. Moreau, Céline Bouvet, Mathieu R. Brodeur, 2013, Journal of Vascular Research.

Dalcetrapib and anacetrapib increase apolipoprotein E-containing HDL in rabbits and humans

J. Tardif, É. Rhéaume, A. Fortier, 2022, Journal of lipid research.

Lipoprotein (a): When to Measure and How to Treat?

J. Tardif, D. Rhainds, Mathieu R. Brodeur, 2021, Current Atherosclerosis Reports.

ADCY9 (Adenylate Cyclase Type 9) Inactivation Protects From Atherosclerosis Only in the Absence of CETP (Cholesteryl Ester Transfer Protein)

S. Lévesque, J. Tardif, M. Dubé, 2018, Circulation.

Lipids, Apolipoproteins, and Inflammatory Biomarkers of Cardiovascular Risk: What Have We Learned?

J. Tardif, D. Rhainds, Mathieu R. Brodeur, 2018, Clinical pharmacology and therapeutics.

Role of Adenylate Cyclase 9 in the Pharmacogenomic Response to Dalcetrapib

M. Pfeffer, F. Sacks, J. Tardif, 2021, Circulation. Genomic and precision medicine.

Development of a new bioactivatable fluorescent probe for quantification of apolipoprotein A-I proteolytic degradation in vitro and in vivo.

J. Tardif, F. Lesage, É. Rhéaume, 2017, Atherosclerosis.

Evaluation of Links Between High-Density Lipoprotein Genetics, Functionality, and Aortic Valve Stenosis Risk in Humans

Y. Bossé, J. Tardif, P. Pibarot, 2014, Arteriosclerosis, thrombosis, and vascular biology.

An update on the clinical development of dalcetrapib (RO4607381), a cholesteryl ester transfer protein modulator that increases HDL cholesterol levels.

J. Tardif, D. Rhainds, B. Arsenault, 2012, Future cardiology.

Genotype-Dependent Effects of Dalcetrapib on Cholesterol Efflux and Inflammation

J. Tardif, M. Dubé, M. Guertin, 2016, Circulation. Cardiovascular genetics.

Mouse CD36 Has Opposite Effects on LDL and Oxidized LDL Metabolism In Vivo

D. Rhainds, L. Brissette, Mathieu R. Brodeur, 2008, Arteriosclerosis, thrombosis, and vascular biology.

In vivo cholesteryl ester selective uptake of mildly and standardly oxidized LDL occurs by both parenchymal and nonparenchymal mouse hepatic cells but SR-BI is only responsible for standardly oxidized LDL selective uptake by nonparenchymal cells.

L. Falstrault, L. Brissette, G. Bourret, 2006, The international journal of biochemistry & cell biology.

Dalcetrapib and anacetrapib differently impact HDL structure and function in rabbits and monkeys[S]

J. Tardif, É. Rhéaume, D. Rhainds, 2017, Journal of Lipid Research.

ApoA-I mimetic does not improve left ventricular diastolic dysfunction in rabbits without aortic valve stenosis.

J. Tardif, M. Guertin, É. Rhéaume, 2021, International journal of cardiology.

HDL mimetic peptide CER-522 treatment regresses left ventricular diastolic dysfunction in cholesterol-fed rabbits.

J. Tardif, É. Rhéaume, N. Lalwani, 2016, International journal of cardiology.

Mouse CD36 Has Opposite Effects on LDL and Oxidized LDL Metabolism In Vivo

D. Rhainds, L. Brissette, Mathieu R. Brodeur, 2008, Arteriosclerosis, thrombosis, and vascular biology.

The interleukin-1β modulator gevokizumab reduces neointimal proliferation and improves reendothelialization in a rat carotid denudation model.

J. Tardif, F. Roubille, É. Rhéaume, 2014, Atherosclerosis.